Marina A. Darenskaya, Russian Federation
Scientific Centre for Family Health and Human Reproduction Problems Pathophysiology DepartmentPresenter of 3 Presentations
CYSTEINE VARIOUS FRACTIONS LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC LOWER EXTREMITIES MICROANGIOPATHY
Abstract
Background and Aims
Oxidative stress can significantly influence lower extremities microangiopathy development in patients with type 2 diabetes (T2DM). Total cysteine and its various fractions levels can serve as an indicator of the plasma antioxidant potential. Cysteine various fractions levels in patients with T2DM and microangiopathy of the lower extremities was the aim of this research.
Methods
60 men from 55 to 70 years old were examined: 20 patients with T2DM without vascular complications and 40 patients with vascular complications - microangiopathy of the lower extremities of the 1st degree. The control group included 20 healthy men. Methods of high-performance liquid chromatography were used.
Results
The level of total cysteine in patients with T2DM without complications decreased (1.76 times) compared to the control group level and relatively increased in T2DM patients with complications (1.16 times to the control group) . The level of the reduced cysteine fraction in patients with complications decreased by 1.75 times to the group without complications. The level of the oxidized fraction increased both in the group without complications (1.88 times) and in the group with complications (2.04 times) relative to the control. The ratio of the reduced fraction to the oxidized fraction decreased by 2.43 times in the group without complications and by 3 times in the group with complications relative to the control.
Conclusions
The content of total cysteine and its reduced fractions significantly decreases in patients with type 2 diabetes with complications in the form of microangiopathy of the lower extremities, which needs to be corrected with antioxidant drugs.
GLYOXAL, METHYLGLYOXAL AND MALONIC DIALDEHYDE DYNAMICS IN PATIENTS WITH DIABETES MELLITUS AND MICROANGIOPATHY OF THE LOWER EXTREMITIES WITH N-ACETYLCYSTEINE CORRECTION
Abstract
Background and Aims
Activation of the hexosamine pathway of glucose metabolism in hyperglycemia leads to the formation of glyoxal, methylglyoxal, and later malonic dialdehyde. These products have a negative effect on the blood vessels wall in patients with type 2 diabetes mellitus (T2DM). The aim of the study was to evaluate the effectiveness of the antioxidant drug N-acetylcysteine in patients with T2DM and lower extremities microangiopathy for correction of glyoxal, metiglyoxal and malonic dialdehyde levels.
Methods
20 men with T2DM and lower extremities microangiopathy with N-acetylcysteine treatment combined with recommended therapy and 30 healthy men (control group) in the study were involved. N-acetylcysteine administered in a daily dose of 600 mg intravenously for 7 days. Methods of high-performance liquid chromatography used.
Results
In patients with T2DM and lower extremities microangiopathy, the glyoxal level increased to the third day (by 56%) and decreased to the control values to the seventh day. The level of methylglyoxal did not change to the third day, but decreased by 5 times to the seventh day. The dynamics of the malonic dialdehyde level decreased on the third (by 15%) and seven (by 47%) days.
Conclusions
The use of N-acetylcysteine allows to decrease the amount of ketoaldehydes in the blood and, thereby, to reduce the manifestation of vascular complications.
25-HYDROXYVITAMIN D AND THYROID HORMONES BLOOD LEVELS IN PATIENTS WITH DIABETIC NEPHROPATHY
Abstract
Background and Aims
Chronic kidney disease (CKD) is considered as an important factor in the disruption of the synthesis and regulation of 25(OH) vitamin D. Also, in patients with CKD terminal stage the thyroid function decrease is considered as one of the risk factors of adverse outcomes. Comparative analysis of the vitamin 25(OH)D and thyroid hormones levels in patients with diabetes mellitus and CKD was this research aim
Methods
Patients with type 1 and type 2 diabetes mellitus (DM) (n = 14, average age 54.5 years) and comparison group without carbohydrate metabolism disorders (n = 17, average age 52 of the year) were examined. In both groups, patients had a terminal stage of CKD and received renal replacement (лучше substitution therapy) therapy. The thyroid-stimulating hormone, thyroxine levels and vitamin 25(OH)D in the blood were determined
Results
The incidence of severe deficiency of vitamin 25(OH)D in the group of patients with DM was higher (81.8%) compared with the group of patients without DM (45.5%) (p<0.05). Correlation analysis revealed the presence of a feedback relations between the content of vitamin 25(OH)D in the blood and the daily average glycaemia in patients with DM (r=-0.66, p<0.05). An analysis of the thyroid hormones profile revealed thyroid hypofunction - subclinical hypothyroidism in 28.5% of all examined patients. A comparative analysis of this parameters not detected statistically significant differences (p>0.05) between two groups.
Conclusions
High prevalence of vitamin 25(OH)D deficiency in patients with end-stage renal failure and DM were found. More than a quarter of patients receiving renal substitution therapy had subclinical hypothyroidism.